Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1987-11-5
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0277-5379
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
577
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3653180-Adult,
pubmed-meshheading:3653180-Aged,
pubmed-meshheading:3653180-Carcinoma, Squamous Cell,
pubmed-meshheading:3653180-Drug Evaluation,
pubmed-meshheading:3653180-Etoposide,
pubmed-meshheading:3653180-Female,
pubmed-meshheading:3653180-Head and Neck Neoplasms,
pubmed-meshheading:3653180-Humans,
pubmed-meshheading:3653180-Male,
pubmed-meshheading:3653180-Middle Aged
|
pubmed:year |
1987
|
pubmed:articleTitle |
Phase II trial of VP16-213 in squamous cell carcinoma of the head and neck.
|
pubmed:publicationType |
Journal Article
|